On Apr. 27, 2020, ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAXﾮ and SplitCore. METAVAXﾮ is the companyﾴs platform for the development of vaccines built on enveloped virus-like particle nanostructures based on the duck Hepatitis B small surface antigen. SplitCore is the technology where capsid virus-like particles are applied as antigen presentation vehicles without involvement of host lipid membrane structures.